Theriva Biologics, Inc. (TOVX)

Theriva Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	23.28	41.89	67.33	6.23	15.05
Cash & Cash Equivalents	23.28	41.89	67.33	6.23	15.05
Cash Growth	-44.42%	-37.79%	981.18%	-58.61%	-47.97%
Other Current Assets	4.12	3.64	1.53	1.71	1.38
Total Current Assets	27.4	45.52	68.86	7.93	16.43
Property, Plant & Equipment	2.18	1.54	1.48	0.45	0.79
Goodwill and Intangibles	5.7	5.53	0	0	0
Other Long-Term Assets	19.94	19.27	0.02	0.02	0.02
Total Long-Term Assets	27.82	26.34	1.51	0.48	0.81
Total Assets	55.22	71.86	70.37	8.41	17.24
Accounts Payable	0.77	0.92	0.52	0.89	2.32
Current Debt	0.55	0.27	0.12	0.29	0.25
Other Current Liabilities	5.42	5.87	2.91	1.79	2.71
Total Current Liabilities	6.74	7.06	3.55	2.97	5.28
Long-Term Debt	1.6	1.41	1.4	0.19	0.47
Other Long-Term Liabilities	7.18	8.83	0	0	0
Total Long-Term Liabilities	8.78	10.24	1.4	0.19	0.47
Total Liabilities	15.52	17.3	4.96	3.15	5.75
Total Debt	2.15	1.68	1.53	0.47	0.72
Debt Growth	28.14%	10.09%	222.83%	-34.49%	-
Retained Earnings	-309.32	-290.97	-271.28	-248.09	-235.54
Comprehensive Income	0.03	-0.68	0	0	0
Shareholders' Equity	36.96	51.83	65.41	-4.77	1.82
Net Cash / Debt	21.13	40.2	65.8	5.75	14.32
Net Cash / Debt Growth	-47.46%	-38.90%	1043.52%	-59.83%	-50.47%
Net Cash Per Share	1.31	2.62	5.40	3.03	8.71
Working Capital	20.67	38.46	65.3	4.97	11.15
Book Value Per Share	2.29	3.38	5.37	-2.51	1.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).